Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD.

BACKGROUND Serum albumin (S-Alb), C-reactive protein (CRP), and interleukin 6 (IL-6) predict malnutrition, atherosclerotic cardiovascular disease (CVD), and mortality in patients with end-stage renal disease (ESRD). Fetuin A, an inhibitor of vascular calcification, also is associated strongly with clinical outcome in patients with ESRD. In this study, multivariate analyses were performed to assess these 4 biomarkers as predictors of malnutrition, CVD, and mortality in patients with ESRD. METHODS One hundred seventy-six patients with ESRD (54 +/- 12 years) underwent measurements of S-Alb, high-sensitivity CRP (hs-CRP), plasma IL-6, and fetuin A close to the start of dialysis therapy and were followed up for a median of 26 months (range, 1 to 66 months). Nutritional status was evaluated by means of subjective global assessment. CVD was defined based on medical history. Associations between biomarker levels and malnutrition, CVD, and mortality were evaluated by means of receiver operating characteristic curve, logistic regression analysis, and Cox proportional hazards model. RESULTS All 4 biomarkers predicted malnutrition, CVD, and mortality. Multivariate analysis, according to receiver operating characteristic analysis, showed that malnutrition was predicted best by hs-CRP and IL-6 levels; CVD, by IL-6 level; and mortality, by albumin and IL-6 levels. When using the cutoff levels derived from receiver operating characteristics, logistic regression analysis showed that only hs-CRP level (odds ratio [OR], 3.6) was associated with malnutrition, and only IL-6 level (OR, 3.7) was associated with CVD. Levels of S-Alb, IL-6, and fetuin A, but not hs-CRP, were associated with increased relative risk for mortality as assessed by Cox in a model adjusting for age, sex, and diabetes mellitus. CONCLUSION Multivariate analyses show that in patients with ESRD, malnutrition is predicted best by hs-CRP and IL-6 levels; CVD, by IL-6 level; and mortality, by S-Alb, IL-6, and fetuin A levels, but not by hs-CRP level. This comparative analysis indicates that of these biomarkers, IL-6 level may be the most reliable predictor of CVD and mortality in patients with ESRD.

[1]  T. Ikizler,et al.  Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. , 2004, Kidney international.

[2]  P. Ridker,et al.  Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. , 2000, Circulation.

[3]  G. Kaysen,et al.  Inflammation in ESRD: causes and potential consequences. , 2003, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[4]  J. Walls,et al.  End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? , 2001, Kidney international.

[5]  J A Swets,et al.  Measuring the accuracy of diagnostic systems. , 1988, Science.

[6]  B. Jaber,et al.  Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  D. Serur,et al.  Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  P. Stenvinkel,et al.  Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. , 1999, Kidney international.

[9]  T. Ikizler,et al.  Nutrition in end-stage renal disease. , 1996, Kidney international.

[10]  C. Tetta,et al.  C-Reactive Protein and Interleukin-6 Levels Are Related to Renal Function in Predialytic Chronic Renal Failure , 2002, Nephron.

[11]  N. Obuchowski.  Receiver operating characteristic curves and their use in radiology. , 2003, Radiology.

[12]  M. Girndt,et al.  Impaired cellular immune function in patients with end-stage renal failure. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  G. Kaysen.  Biological basis of hypoalbuminemia in ESRD. , 1998, Journal of the American Society of Nephrology : JASN.

[14]  V. Panichi,et al.  The link of biocompatibility to cytokine production. , 2000, Kidney international. Supplement.

[15]  A. Collins.  Cardiovascular Mortality in End-Stage Renal Disease , 2003, The American journal of the medical sciences.

[16]  P. Stenvinkel,et al.  IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly. , 2005, Kidney international.

[17]  Gary L Myers,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[18]  U. Maggiore,et al.  Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  T. Ishimitsu,et al.  Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors. , 2003, Atherosclerosis.

[20]  A. Schwarz,et al.  The serum protein α2–Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification , 2003 .

[21]  C. Wanner,et al.  Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study , 2003, The Lancet.

[22]  C. Visser,et al.  C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. , 1997, Circulation.

[23]  J. Plutzky.  Inflammatory pathways in atherosclerosis and acute coronary syndromes. , 2001, The American journal of cardiology.

[24]  R. Mortensen.  C-reactive protein, inflammation, and innate immunity , 2001, Immunologic research.

[25]  Paul M. Ridker,et al.  C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003 .

[26]  T. Stompór,et al.  Selected Growth Factors in Peritoneal Dialysis: Their Relationship to Markers of Inflammation, Dialysis Adequacy, Residual Renal Function, and Peritoneal Membrane Transport , 2002, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[27]  J. Weatherbee,et al.  Circadian characteristics of interleukin-6 in blood and urine of clinically healthy men. , 1995, In vivo.

[28]  J. Raoult,et al.  Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. , 1979, The Journal of clinical investigation.

[29]  M. Hori,et al.  C-Reactive Protein Is an Independent Predictor of the Rate of Increase in Early Carotid Atherosclerosis , 2001, Circulation.

[30]  D. Nicol,et al.  Is C-reactive protein a useful predictor of outcome in peritoneal dialysis patients? , 2001, Journal of the American Society of Nephrology : JASN.

[31]  W. Owen,et al.  C-reactive protein as an outcome predictor for maintenance hemodialysis patients. , 1998, Kidney international.

[32]  T. Ikizler,et al.  Approaches to the reversal of malnutrition, inflammation, and atherosclerosis in end-stage renal disease. , 2002, Nutrition reviews.

[33]  P. Kimmel,et al.  Immunologic function and survival in hemodialysis patients. , 1998, Kidney international.

[34]  B. Lindholm,et al.  Factors predicting malnutrition in hemodialysis patients: a cross-sectional study. , 1998, Kidney international.

[35]  C. Vrints,et al.  Chronic heart failure: an example of a systemic chronic inflammatory disease resulting in cachexia. , 2002, International journal of cardiology.

[36]  Edward T H Yeh,et al.  Coming of age of C-reactive protein: using inflammation markers in cardiology. , 2003, Circulation.

[37]  P. Stenvinkel,et al.  Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. , 2005, Kidney international.

[38]  George A Kaysen,et al.  Relationships among inflammation nutrition and physiologic mechanisms establishing albumin levels in hemodialysis patients. , 2002, Kidney international.

[39]  J. Woo,et al.  Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients? , 2003, Journal of the American Society of Nephrology : JASN.

[40]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[41]  C. Wanner,et al.  Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. , 1999, Kidney international.